Appili Therapeutics, the biopharmaceutical company focused on drug development for infectious diseases, and AiPharma have announced a strategic alliance to advance the global development of Avigan®/Reeqonus™ (favipiravir), a broad-spectrum oral antiviral potential treatment and prevention of COVID-19.
Appili Therapeutics and AiPharma have entered a strategic collaboration to progress the international development of Avigan/Reeqonus (favipiravir).
AAIPharma Services Corp./Cambridge Major Laboratories, Inc. (AAI/CML), a leading provider of custom manufacturing and development services for the pharmaceutical and biotechnology industries, today announces expanded sterile fill-finish capabilities and capacity in its Charleston, SC site. Substantial growth in demand has driven several recent investments.nWhen AAI/CML acquired the Charleston facility in 2001 it had one filling line with small-scale lyophilization. The site has invested in significant upgrades to equipment and staff since, including a small scale lyophilizer for cycle development studies conducted by an expert formulation development (FDL) team on site. Customers requiring lyophilization receive the benefits of quick turnaround times from an experienced staff that also supports sterile filling and GMP manufacturing.
AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. (AAI/CML), a leading provider of custom manufacturing and development services for the pharmaceutical and biotechnology industries, announced today an integrated service offering for solid state chemistry and formulation development to help the pharma/biotech industry meet important milestones and maintain stability in drug development. ProForm Select™ aligns our solid-state, process chemistry and formulation development centers of excellence in Weert, The Netherlands, Germantown, Wisconsin and Wilmington, North Carolina. These groups are focused on designing efficient, robust and scalable processes to progress Active Pharmaceutical Ingredients (APIs) from early development to final dosage form.
AAIPharma Services Corp./Cambridge Major Laboratories, Inc. (AAI/CML), a leading provider of custom manufacturing and development services for the pharmaceutical and biotechnology industries, today announces additional capabilities and capacity for oral solid manufacturing in its Wilmington, NC facility. These investments have been driven by the significant growth in our drug product portfolio, particularly for orphan drugs and rare disease therapies.
Major Laboratories, Inc. (AAIPharma / CML) today announced the planned investment of at least $ 15.8 million in the expansion of the laboratory and its global headquarters in Wilmington, NC. The expansion will result in additional office space and additional capacity development services to meet the growing needs of the pharmaceutical and biotechnology markets.